Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| (NASDAQ: NVCT) | Delayed: 20.70 +0.11 (0.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.59 | 52 Week High | $ | |||
| Open | $20.63 | 52 Week Low | $ | |||
| Day High | $21.72 | P/E | N/A | |||
| Day Low | $19.94 | EPS | $ | |||
| Volume | 203,582 | |||||
